Znaczenie interwencji żywieniowej dla procesu terapeutycznego chorych na nowotwory hematologiczne Review article
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 10, 2017
Słowa kluczowe:
interwencja żywieniowa, pacjenci, nowotwory hematologiczne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zachorowalność na nowotwory, w tym również te należące do niezwykle zróżnicowanej grupy nowotworów hematologicznych, w populacji światowej stale wzrasta. Istotną kwestią jest fakt, iż w ich wyniku najczęściej dochodzi do mimowolnej utraty masy ciała, której następstwem są nieprawidłowości stanu odżywienia pacjenta oraz związane z nimi: powikłania pooperacyjne, zmniejszona odpowiedź na leczenie, zwiększone ryzyko upadków, zakażeń szpitalnych, obniżenie jakości życia i wzrost ryzyka zgonu. Dlatego należy dążyć do identyfikacji zaburzeń stanu odżywienia pacjenta, co pozwoli na wdrożenie właściwej interwencji żywieniowej, a dzięki temu – na poprawę wyników klinicznych oraz terapeutycznych. Ważne jest przy tym ustalanie dietoterapii na podstawie bieżącego stanu zdrowia, występujących niedoborów i zaburzeń, planowanego okresu żywienia oraz możliwości przygotowania i spożycia poszczególnych posiłków.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Szeja N, Grosicki S. Znaczenie interwencji żywieniowej dla procesu terapeutycznego chorych na nowotwory hematologiczne. OncoReview [Internet]. 10 wrzesień 2017 [cytowane 23 listopad 2024];7(4(28):184-91. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/459
Numer
Dział
HAEMATOLOGY IN ONCOLOGY
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. International Agency for Research on Cancer World Health Organization. World Cancer Report 2014. Lyon 2014.
2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-386. https://doi.org/10.1002/ijc.29210.
3. Wojciechowska U, Olasek P, Czauderna K et al. Nowotwory złośliwe w Polsce w 2014 roku. Krajowy Rejestr Nowotworów. Zakład Epidemiologii i Prewencji Nowotworów, Warszawa 2016.
4. Kiełczewski T, Dylewska M, Kurek B et al. Dostęp pacjentów onkologicznych do terapii lekowych w Polsce na tle aktualnej wiedzy medycznej. PEX PharmaSequence, 2017. Znaczenie interwencji żywieniowej dla procesu terapeutycznego chorych na nowotwory hematologiczne.
5. de Quadros Camargo C, da Silva Borges D, de Oliveira PF et al. Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutr Cancer 2015; 67(3): 463-471. https://doi.org/10.1080/01635581.2015.1004732.
6. Pulgar Á, Alcalá A, Reyes Del Paso GA. Psychosocial predictors of quality of life in hematological cancer. Behav Med 2015; 41(1): 1-8. https://doi.org/10.1080/08964289.2013.833083.
7. Mauro FR, Salaroli A, Caputo MD et al. Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Rev Hematol 2016; 9(12): 1165-1175.
8. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol 2012; 96: 186-193. https://doi.org/10.1007/s12185-012-1137-3.
9. Lindman A, Rasmussen HB, Andersen NF. Food caregivers influence on nutritional intake among admitted hematological cancer patients – a prospective study. Eur J Oncol Nurs 2013; 17(6): 827-834. https://doi.org/10.1016/j.ejon.2013.06.010.
10. Baumgartner A, Zueger N, Bargetzi A et al. Association of Nutritional Parameters with Clinical Outcomes in Patients with Acute Myeloid Leukemia Undergoing Haematopoietic Stem Cell Transplantation. Ann Nutr Metab 2016; 69: 89-98. https://doi.org/10.1159/000449451.
11. Kłęk S, Jankowski M, Kruszewski WJ et al. Standardy leczenia żywieniowego w onkologii. Nowotwory 2015; 65(4): 320-337. https://doi.org/10.5603/NJO.2015.0062.
12. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res 2009; 16(1): 1-12. https://doi.org/10.1093/dnares/dsn033.
13. Stauder R, Eichhorst B, Hamaker ME et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol 2017; 28(2): 218-227. https://doi.org/10.1093/annonc/mdw547.
14. Kim H, Kataru RP, Koh GY. Inflammation-associated lymphangiogenesis: a double-edged sword? J Clin Invest 2014; 124(3): 936-942. https://doi.org/10.1172/JCI71607.
15. Skipworth RJ, Stewart DF, Dejong CH et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 26(6): 667-676. https://doi.org/10.1016/j.clnu.2007.03.011.
16. Esfahani A, Ghoreishi Z, Nikanfar A et al. Influence of chemotherapy on the lipid peroxidation and antioxidant status in patients with acute myeloid leukemia. Acta Med Iran 2012; 50(7): 454-458.
17. Gröber U, Holzhauer P, Kisters K et al. Micronutrients in Oncological Intervention. Nutrients 2016; 8(3): 163. https://doi.org/10.3390/nu8030163.
18. Davidson W, Teleni L, Muller J et al. Malnutrition and chemotherapy-induced nausea and vomiting: implications for practice. Oncol Nurs Forum 2012; 39(4): E340-345. https://doi.org/10.1188/12.ONF.E340-E345.
19. Marx W, Kiss N, McCarthy AL et al. Chemotherapy-Induced Nausea and Vomiting: A Narrative Review to Inform Dietetics Practice. J Acad Nutr Diet 2016; 116(5): 819-827. https://doi.org/10.1016/j.jand.2015.10.020.
20. Gujski M (ed), Kobosz T, Kielar M, Szeligowska J. Raport Instytutu Ochrony Zdrowia w Polsce. Leczenie wspomagające u chorych na nowotwory. Część 1. Nudności i wymioty. Warszawa 2016.
21. Kalinka-Warzocha E, Warzocha K. Zasady profilaktyki nudności i wymiotów indukowanych chemioterapią i radioterapią u chorych leczonych z powodu nowotworów układów krwiotwórczego i chłonnego. Hematologia 2014; 5(4): 332-339.
22. Kawecki A, Krzakowski N. Nudności i wymioty związane z chemioterapią i radioterapią. W: Krzakowski M, Warzocha K (ed). Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Via Medica, Gdańsk 2013.
23. Parasa K, Avvaru K. Assessment of Nutritional Status of Cancer Patients Using Scored PG-SGA Tool. IOSR-JDMS 2016; 15(8): 37-40. https://doi.org/10.9790/0853-1508013740.
24. Liu P, Zhang Z-F, Cai J-J et al. NRS2002 assesses nutritional status of leukemia patients undergoing hematopoietic stem cell transplantation. Chin J Cancer Res 2012; 24(4): 299-303. https://doi.org/10.3978/j.issn.1000-9604.2012.09.01.
25. Lis CG, Gupta D, Lammersfeld CA et al. Role of nutritional status in predicting quality of life outcomes in cancer – a systematic review of the epidemiological literature. Nutr J 2012; 11: 27. https://doi.org/10.1186/1475-2891-11-27.
26. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J. Cachexia Sarcopenia Muscle 2010; 1: 1-5. https://doi.org/10.1007/s13539-010-0002-6.
27. Prevost V, Joubert C, Heutte N et al. Assessment of nutritional status and quality of life in patients treated for head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131(2): 113-120. https://doi.org/10.1016/j.anorl.2013.06.007.
28. Bozetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol 2013; 87(2): 172-200. https://doi.org/10.1016/j.critrevonc.2013.03.006.
29. Ebling B, Brumnić V, Rendić-Miocević Z et al. Assessment of nutritional status in cancer patients in Osijek health area center. Collegium Antropologicum 2014; 38(1): 105-110.
30. Uster A, Ruefenacht U, Ruehlin M et al. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: A randomized controlled trial. Nutr 2013; 29: 1342-1349. https://doi.org/10.1016/j.nut.2013.05.004.
31. Muscaritoli M, Krznarić Z, Barazzoni R et al. Effectiveness and efficacy of nutritional therapy – A cochrane systematic review. Clin Nutr 2016; pii: S0261-5614(16)30157-1. https://doi.org/10.1016/j.clnu.2016.06.022.
32. Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J. Cachexia Sarcopenia Muscle 2011; 2: 27-35. https://doi.org/10.1007/s13539-011-0022-x.
33. Donini LM, Ricciardi LM, Neri B et al. Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool. Clin Nutr 2014; 33(6): 1087-1094. https://doi.org/10.1016/j.clnu.2013.12.001.
34. Brunner AM, Sadrzadeh H, Feng Y et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 2013; 88(8): 642-646. https://doi.org/10.1002/ajh.23462.
35. Kanemasa Y, Shimoyama T, Sasaki Y et al. Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients. Hematol Oncol 2017: 1-8. https://doi.org/10.1002/hon.2426.
36. Gupta D, Vashi PG, Lammersfeld CA et al. Role of Nutritional Status in Predicting the Length of Stay in Cancer: A Systematic Review of the Epidemiological Literature. Ann Nutr Metab 2011; 59: 96-106. https://doi.org/10.1159/000332914.
37. Andreoli A, De Lorenzo A, Cadeddu F et al. New trends in nutritional status assessment of cancer patients. Eur Rev Med Pharmacol Sci 2011; 15(5): 469-480.
38. Lewandowska A, Woźniak AE. Leczenie żywieniowe u chorych na nowotwory układów krwiotwórczego i chłonnego. Hematologia 2016; 7(3): 243-249. https://doi.org/10.5603/Hem.2016.0020.
39. Kłęk S, Jarosz J, Jassem J et al. Polskie Rekomendacje Żywienia Dojelitowego i Pozajelitowego w Onkologii. Część II: Żywienie drogą przewodu pokarmowego (żywienie dojelitowe). Onkol Prak Klin 2013; 9(6): 209-215.
40. Ward EJ, Henry LM, Friend AJ et al. Nutritional support in children and young people with cancer undergoing chemotherapy. Cochrane Database Syst Rev 2015; (8): CD003298. https://doi.org/10.1002/14651858.CD003298.pub3.
41. Malihi Z, Kandiah M, Chan YM et al. Nutritional status and quality of life in patients with acute leukaemia prior to and after induction chemotherapy in three hospitals in Tehran, Iran: a prospective study. J Hum Nutr Diet 2013; 26 Suppl 1: 123-131. https://doi.org/10.1111/jhn.12043.
42. Omlin A, Blum D, Wierecky J et al. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle 2013; 4(1): 55-61. https://doi.org/10.1007/s13539-012-0099-x.
43. Prockmann S, Ruschel Freitas AH, Gonçalves Ferreira M et al. Evaluation of diet acceptance by patients with haematological cancer during chemotherapeutic treatment. Nutr Hosp 2015; 32(2): 779-784. https://doi.org/10.3305/nh.2015.32.2.8958.
44. Ferreira D, Guimarães TG, Marcadenti A. Acceptance of hospital diets and nutritional status among inpatients with cancer. Einstein (Sao Paulo) 2013; 11(1): 41-46.
45. Kim R, Emi M, Tanabe K et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66(11): 5527-5536.
46. Hall A, Lynagh M, Tzelepis F et al. How can we help haematological cancer survivors cope with the changes they experience as a result of their cancer? Ann Hematol 2016; 95(12): 2065-2076. https://doi.org/10.1007/s00277-016-2806-8.
47. Nørgaard M. Risk of Infections in Adult Patients with Haematological Malignancies. Open Inf Dis J 2012; 6: 46-51. https://doi.org/10.2174/1874279301206010046.
48. Mizock BA. Immunonutrition and critical illness: an update. Nutrition 2010; 26(7-8): 701-707. https://doi.org/10.1016/j.nut.2009.11.010.
49. Nowak ZJ. Przeciwzapalne „prowygaszeniowe” pochodne wielonienasyconych kwasów tłuszczowych omega 3 i omega 6. Postępy Hig Med Dosw 2010; 64: 115-132.
50. Abdi J, Garssen J, Faber J et al. Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. J Nutr Biochem 2014; 25(12): 1254-1262. https://doi.org/10.1016/j.jnutbio.2014.06.013.
51. Manzanares W, Dhaliwal R, Jurewitsch B et al. Alternative lipid emulsions in the critically ill: a systematic review of the evidence. Intensive Care Med 2013; 39: 1683-1694. https://doi.org/10.1007/s00134-013-2999-4.
52. Palmer AJ, Clement KM, Ajibola O et al. The role of omega-3 fatty acid supplemented parenteral nutrition in critical illness in adults: a systematic review and meta-analysis. Crit Care Med 2013; 41: 307-316. https://doi.org/10.1097/CCM.0b013e3182657578.
53. Manzanares W, Dhaliwal R, Jurewitsch B et al. Parenteral fish oil in the critically ill: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr 2014; 38: 20-28. https://doi.org/10.1177/0148607113486006.
54. Wischmeyer PE. Glutamine: mode of action in critical illness. Crit Care Med 2007; 35(9 suppl): S54-S544.
55. Tao KM, Li XQ, Yang LQ et al. Glutamine supplementation for critically ill adults. Cochrane Database Syst Rev 2014; (9): CD010050. https://doi.org/10.1002/14651858.CD010050.pub2.
56. Heyland D, Muscedere J, Wischmeyer PE et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368: 1489-1497. https://doi.org/10.1056/NEJMoa1212722.
57. van Zanten AH, Sztark F, Kaisers UX et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA 2014; 312: 514-524. https://doi.org/10.1001/jama.2014.7698.
58. van Zanten AR, Hofman Z, Heyland DK. Consequences of the REDOXS and METAPLUS Trials: The End of an Era of Glutamine and Antioxidant Supplementation for Critically Ill Patients? JPEN J Parenter Enteral Nutr 2015; 39(8): 890-892. https://doi.org/10.1177/0148607114567201.
59. Popovic PJ, Zeh HJ, Ochoa JB. Arginine and immunity. J. Nutr 2007; 137(suppl): 1681S-1686S.
60. Annetta MG, Pittiruti M, Vecchiarelli P et al. Immunonutrients in critically ill patients: an analysis of the most recent literature. Minerva Anestesiol 2016; 82(3): 320-331.
61. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of literature. Intensive Care Med 2008; 11: 1980-1990. https://doi.org/10.1007/s00134-008-1213-6.
62. > Dhaliwal R, Cahill N, Lemieux M et al. The Canadian Critical Care Nutrition Guidelines in 2013: an update on current recommendations and implementation strategies. Nutr Clin Pract 2014; 29: 29-43. https://doi.org/10.1177/0884533613510948 63. Korczyk M, Paśko P, Zachwieja Z. Interakcje witamin z grupy B z wybranymi lekami przeciwnowotworowymi. Bromat Chem Toksykol 2016; 49(3): 693-697.
64. Segal EM, Flood MR, Mancini RS et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract 2014; 10(4): e255-268. https://doi.org/10.1200/JOP.2013.001183.
65. Pulcini CD, Zettle S, Srinath A. Refeeding Syndrome. Pediatr Rev 2016; 37(12): 516-523. https://doi.org/10.1542/pir.2015-0152.
66. Friedli N, Stanga Z, Sobotka L et al. Revisiting the refeeding syndrome: Results of a systematic review. Nutrition 2017; 35: 151-160. https://doi.org/10.1016/j.nut.2016.05.016.
67. Boateng AA, Sriram K, Meguid MM et al. Refeeding syndrome: treatment considerations based on collective analysis of literature case reports. Nutrition 2010; 26(2): 156-167. https://doi.org/10.1016/j.nut.2009.11.017.
2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-386. https://doi.org/10.1002/ijc.29210.
3. Wojciechowska U, Olasek P, Czauderna K et al. Nowotwory złośliwe w Polsce w 2014 roku. Krajowy Rejestr Nowotworów. Zakład Epidemiologii i Prewencji Nowotworów, Warszawa 2016.
4. Kiełczewski T, Dylewska M, Kurek B et al. Dostęp pacjentów onkologicznych do terapii lekowych w Polsce na tle aktualnej wiedzy medycznej. PEX PharmaSequence, 2017. Znaczenie interwencji żywieniowej dla procesu terapeutycznego chorych na nowotwory hematologiczne.
5. de Quadros Camargo C, da Silva Borges D, de Oliveira PF et al. Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutr Cancer 2015; 67(3): 463-471. https://doi.org/10.1080/01635581.2015.1004732.
6. Pulgar Á, Alcalá A, Reyes Del Paso GA. Psychosocial predictors of quality of life in hematological cancer. Behav Med 2015; 41(1): 1-8. https://doi.org/10.1080/08964289.2013.833083.
7. Mauro FR, Salaroli A, Caputo MD et al. Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Rev Hematol 2016; 9(12): 1165-1175.
8. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol 2012; 96: 186-193. https://doi.org/10.1007/s12185-012-1137-3.
9. Lindman A, Rasmussen HB, Andersen NF. Food caregivers influence on nutritional intake among admitted hematological cancer patients – a prospective study. Eur J Oncol Nurs 2013; 17(6): 827-834. https://doi.org/10.1016/j.ejon.2013.06.010.
10. Baumgartner A, Zueger N, Bargetzi A et al. Association of Nutritional Parameters with Clinical Outcomes in Patients with Acute Myeloid Leukemia Undergoing Haematopoietic Stem Cell Transplantation. Ann Nutr Metab 2016; 69: 89-98. https://doi.org/10.1159/000449451.
11. Kłęk S, Jankowski M, Kruszewski WJ et al. Standardy leczenia żywieniowego w onkologii. Nowotwory 2015; 65(4): 320-337. https://doi.org/10.5603/NJO.2015.0062.
12. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res 2009; 16(1): 1-12. https://doi.org/10.1093/dnares/dsn033.
13. Stauder R, Eichhorst B, Hamaker ME et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol 2017; 28(2): 218-227. https://doi.org/10.1093/annonc/mdw547.
14. Kim H, Kataru RP, Koh GY. Inflammation-associated lymphangiogenesis: a double-edged sword? J Clin Invest 2014; 124(3): 936-942. https://doi.org/10.1172/JCI71607.
15. Skipworth RJ, Stewart DF, Dejong CH et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 26(6): 667-676. https://doi.org/10.1016/j.clnu.2007.03.011.
16. Esfahani A, Ghoreishi Z, Nikanfar A et al. Influence of chemotherapy on the lipid peroxidation and antioxidant status in patients with acute myeloid leukemia. Acta Med Iran 2012; 50(7): 454-458.
17. Gröber U, Holzhauer P, Kisters K et al. Micronutrients in Oncological Intervention. Nutrients 2016; 8(3): 163. https://doi.org/10.3390/nu8030163.
18. Davidson W, Teleni L, Muller J et al. Malnutrition and chemotherapy-induced nausea and vomiting: implications for practice. Oncol Nurs Forum 2012; 39(4): E340-345. https://doi.org/10.1188/12.ONF.E340-E345.
19. Marx W, Kiss N, McCarthy AL et al. Chemotherapy-Induced Nausea and Vomiting: A Narrative Review to Inform Dietetics Practice. J Acad Nutr Diet 2016; 116(5): 819-827. https://doi.org/10.1016/j.jand.2015.10.020.
20. Gujski M (ed), Kobosz T, Kielar M, Szeligowska J. Raport Instytutu Ochrony Zdrowia w Polsce. Leczenie wspomagające u chorych na nowotwory. Część 1. Nudności i wymioty. Warszawa 2016.
21. Kalinka-Warzocha E, Warzocha K. Zasady profilaktyki nudności i wymiotów indukowanych chemioterapią i radioterapią u chorych leczonych z powodu nowotworów układów krwiotwórczego i chłonnego. Hematologia 2014; 5(4): 332-339.
22. Kawecki A, Krzakowski N. Nudności i wymioty związane z chemioterapią i radioterapią. W: Krzakowski M, Warzocha K (ed). Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Via Medica, Gdańsk 2013.
23. Parasa K, Avvaru K. Assessment of Nutritional Status of Cancer Patients Using Scored PG-SGA Tool. IOSR-JDMS 2016; 15(8): 37-40. https://doi.org/10.9790/0853-1508013740.
24. Liu P, Zhang Z-F, Cai J-J et al. NRS2002 assesses nutritional status of leukemia patients undergoing hematopoietic stem cell transplantation. Chin J Cancer Res 2012; 24(4): 299-303. https://doi.org/10.3978/j.issn.1000-9604.2012.09.01.
25. Lis CG, Gupta D, Lammersfeld CA et al. Role of nutritional status in predicting quality of life outcomes in cancer – a systematic review of the epidemiological literature. Nutr J 2012; 11: 27. https://doi.org/10.1186/1475-2891-11-27.
26. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J. Cachexia Sarcopenia Muscle 2010; 1: 1-5. https://doi.org/10.1007/s13539-010-0002-6.
27. Prevost V, Joubert C, Heutte N et al. Assessment of nutritional status and quality of life in patients treated for head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131(2): 113-120. https://doi.org/10.1016/j.anorl.2013.06.007.
28. Bozetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol 2013; 87(2): 172-200. https://doi.org/10.1016/j.critrevonc.2013.03.006.
29. Ebling B, Brumnić V, Rendić-Miocević Z et al. Assessment of nutritional status in cancer patients in Osijek health area center. Collegium Antropologicum 2014; 38(1): 105-110.
30. Uster A, Ruefenacht U, Ruehlin M et al. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: A randomized controlled trial. Nutr 2013; 29: 1342-1349. https://doi.org/10.1016/j.nut.2013.05.004.
31. Muscaritoli M, Krznarić Z, Barazzoni R et al. Effectiveness and efficacy of nutritional therapy – A cochrane systematic review. Clin Nutr 2016; pii: S0261-5614(16)30157-1. https://doi.org/10.1016/j.clnu.2016.06.022.
32. Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J. Cachexia Sarcopenia Muscle 2011; 2: 27-35. https://doi.org/10.1007/s13539-011-0022-x.
33. Donini LM, Ricciardi LM, Neri B et al. Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool. Clin Nutr 2014; 33(6): 1087-1094. https://doi.org/10.1016/j.clnu.2013.12.001.
34. Brunner AM, Sadrzadeh H, Feng Y et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 2013; 88(8): 642-646. https://doi.org/10.1002/ajh.23462.
35. Kanemasa Y, Shimoyama T, Sasaki Y et al. Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients. Hematol Oncol 2017: 1-8. https://doi.org/10.1002/hon.2426.
36. Gupta D, Vashi PG, Lammersfeld CA et al. Role of Nutritional Status in Predicting the Length of Stay in Cancer: A Systematic Review of the Epidemiological Literature. Ann Nutr Metab 2011; 59: 96-106. https://doi.org/10.1159/000332914.
37. Andreoli A, De Lorenzo A, Cadeddu F et al. New trends in nutritional status assessment of cancer patients. Eur Rev Med Pharmacol Sci 2011; 15(5): 469-480.
38. Lewandowska A, Woźniak AE. Leczenie żywieniowe u chorych na nowotwory układów krwiotwórczego i chłonnego. Hematologia 2016; 7(3): 243-249. https://doi.org/10.5603/Hem.2016.0020.
39. Kłęk S, Jarosz J, Jassem J et al. Polskie Rekomendacje Żywienia Dojelitowego i Pozajelitowego w Onkologii. Część II: Żywienie drogą przewodu pokarmowego (żywienie dojelitowe). Onkol Prak Klin 2013; 9(6): 209-215.
40. Ward EJ, Henry LM, Friend AJ et al. Nutritional support in children and young people with cancer undergoing chemotherapy. Cochrane Database Syst Rev 2015; (8): CD003298. https://doi.org/10.1002/14651858.CD003298.pub3.
41. Malihi Z, Kandiah M, Chan YM et al. Nutritional status and quality of life in patients with acute leukaemia prior to and after induction chemotherapy in three hospitals in Tehran, Iran: a prospective study. J Hum Nutr Diet 2013; 26 Suppl 1: 123-131. https://doi.org/10.1111/jhn.12043.
42. Omlin A, Blum D, Wierecky J et al. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle 2013; 4(1): 55-61. https://doi.org/10.1007/s13539-012-0099-x.
43. Prockmann S, Ruschel Freitas AH, Gonçalves Ferreira M et al. Evaluation of diet acceptance by patients with haematological cancer during chemotherapeutic treatment. Nutr Hosp 2015; 32(2): 779-784. https://doi.org/10.3305/nh.2015.32.2.8958.
44. Ferreira D, Guimarães TG, Marcadenti A. Acceptance of hospital diets and nutritional status among inpatients with cancer. Einstein (Sao Paulo) 2013; 11(1): 41-46.
45. Kim R, Emi M, Tanabe K et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66(11): 5527-5536.
46. Hall A, Lynagh M, Tzelepis F et al. How can we help haematological cancer survivors cope with the changes they experience as a result of their cancer? Ann Hematol 2016; 95(12): 2065-2076. https://doi.org/10.1007/s00277-016-2806-8.
47. Nørgaard M. Risk of Infections in Adult Patients with Haematological Malignancies. Open Inf Dis J 2012; 6: 46-51. https://doi.org/10.2174/1874279301206010046.
48. Mizock BA. Immunonutrition and critical illness: an update. Nutrition 2010; 26(7-8): 701-707. https://doi.org/10.1016/j.nut.2009.11.010.
49. Nowak ZJ. Przeciwzapalne „prowygaszeniowe” pochodne wielonienasyconych kwasów tłuszczowych omega 3 i omega 6. Postępy Hig Med Dosw 2010; 64: 115-132.
50. Abdi J, Garssen J, Faber J et al. Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. J Nutr Biochem 2014; 25(12): 1254-1262. https://doi.org/10.1016/j.jnutbio.2014.06.013.
51. Manzanares W, Dhaliwal R, Jurewitsch B et al. Alternative lipid emulsions in the critically ill: a systematic review of the evidence. Intensive Care Med 2013; 39: 1683-1694. https://doi.org/10.1007/s00134-013-2999-4.
52. Palmer AJ, Clement KM, Ajibola O et al. The role of omega-3 fatty acid supplemented parenteral nutrition in critical illness in adults: a systematic review and meta-analysis. Crit Care Med 2013; 41: 307-316. https://doi.org/10.1097/CCM.0b013e3182657578.
53. Manzanares W, Dhaliwal R, Jurewitsch B et al. Parenteral fish oil in the critically ill: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr 2014; 38: 20-28. https://doi.org/10.1177/0148607113486006.
54. Wischmeyer PE. Glutamine: mode of action in critical illness. Crit Care Med 2007; 35(9 suppl): S54-S544.
55. Tao KM, Li XQ, Yang LQ et al. Glutamine supplementation for critically ill adults. Cochrane Database Syst Rev 2014; (9): CD010050. https://doi.org/10.1002/14651858.CD010050.pub2.
56. Heyland D, Muscedere J, Wischmeyer PE et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368: 1489-1497. https://doi.org/10.1056/NEJMoa1212722.
57. van Zanten AH, Sztark F, Kaisers UX et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA 2014; 312: 514-524. https://doi.org/10.1001/jama.2014.7698.
58. van Zanten AR, Hofman Z, Heyland DK. Consequences of the REDOXS and METAPLUS Trials: The End of an Era of Glutamine and Antioxidant Supplementation for Critically Ill Patients? JPEN J Parenter Enteral Nutr 2015; 39(8): 890-892. https://doi.org/10.1177/0148607114567201.
59. Popovic PJ, Zeh HJ, Ochoa JB. Arginine and immunity. J. Nutr 2007; 137(suppl): 1681S-1686S.
60. Annetta MG, Pittiruti M, Vecchiarelli P et al. Immunonutrients in critically ill patients: an analysis of the most recent literature. Minerva Anestesiol 2016; 82(3): 320-331.
61. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of literature. Intensive Care Med 2008; 11: 1980-1990. https://doi.org/10.1007/s00134-008-1213-6.
62. > Dhaliwal R, Cahill N, Lemieux M et al. The Canadian Critical Care Nutrition Guidelines in 2013: an update on current recommendations and implementation strategies. Nutr Clin Pract 2014; 29: 29-43. https://doi.org/10.1177/0884533613510948 63. Korczyk M, Paśko P, Zachwieja Z. Interakcje witamin z grupy B z wybranymi lekami przeciwnowotworowymi. Bromat Chem Toksykol 2016; 49(3): 693-697.
64. Segal EM, Flood MR, Mancini RS et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract 2014; 10(4): e255-268. https://doi.org/10.1200/JOP.2013.001183.
65. Pulcini CD, Zettle S, Srinath A. Refeeding Syndrome. Pediatr Rev 2016; 37(12): 516-523. https://doi.org/10.1542/pir.2015-0152.
66. Friedli N, Stanga Z, Sobotka L et al. Revisiting the refeeding syndrome: Results of a systematic review. Nutrition 2017; 35: 151-160. https://doi.org/10.1016/j.nut.2016.05.016.
67. Boateng AA, Sriram K, Meguid MM et al. Refeeding syndrome: treatment considerations based on collective analysis of literature case reports. Nutrition 2010; 26(2): 156-167. https://doi.org/10.1016/j.nut.2009.11.017.